Combining AI and MRI to improve human longevity

Combining AI and MRI to improve human longevity

Twinn Health aims to boost healthy longevity by making disease prevention scalable – starting with metabolic disease.

British health tech startup Twinn Health recently emerged from stealth, boasting an AI-powered platform that analyzes MRI scans to detect preventable disease “earlier than ever before.” Starting with metabolic disease, the company’s AI platform leverages validated imaging biomarkers to improve diagnosis and treatment decisions.

With age-related frailty and liver disease also on its roadmap, Twinn Health is positioning itself squarely in the domain of longevity and preventive healthcare. The company is supported by WAED, a $500 million venture capital fund backed by Saudi Aramco, which invests in innovative tech-based startups.

My take on this: Magnetic resonance imaging (MRI) has been used in healthcare for decades and is widely used in hospitals and clinics for the diagnosis and follow-up of disease. In recent years, AI tools have appeared that help identify the presence of specific conditions within MRI scans, but the technology is not yet widely used in healthcare to support healthspan and longevity improvements. Twinn Health aims to change that, combining MRI and AI to enable the early detection and management of multiple age-related diseases. To learn more, we caught up with founder and CEO Dr Wareed Alenaini.

Alenaini is keen to stress that Twinn’s main goal is about helping physicians learn things they might not already be looking for.

“Usually, when you do an MRI today, it’s one MRI scan for one single diagnosis – kidney stones for example,” she says. “So, you do the MRI, the doctor looks at the kidney stones, writes the report, and then the scan data gets archived, and will probably never be checked again.”

“That’s where Twinn comes in – we’re extracting additional insights from MRI scans that may not have been the primary focus of the physician. We’re using technology to make chronic disease prevention scalable.”

Discover the fascinating realm of targeting metabolic dysfunction and longevity through MRI and beyond from Dr Watani herself HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!

Nelson González Contreras

Químico Farmacéutico, U.de Concepción, Ph.D. in Pharmaceutical Sciences U. Basel

1 年

Excellent, Article.

回复

要查看或添加评论,请登录

Phil Newman的更多文章

社区洞察

其他会员也浏览了